



























Cellular senescence is a stable form of cell-cycle arrest 
which is thought to limit the proliferative potential of 
premalignant cells [1]. The senescence phenotype was 
initially described by Hayflick and Moorhead in 1961 
on human fibroblasts undergoing replicative exhaustion 
in culture [2]. It has been shown that senescence can be 
triggered in different cell types in response to diverse 
forms of cellular damage or stress [for review see 1]. 
Importantly, while senescence was denounced as a   
tissue culture phenomenon for many years, recent in 
vivo studies demonstrated that cellular senescence 
represents a potent failsafe mechanism against   
tumorigenesis and contributes to the cytotoxicity of 
certain anticancer agents [see for example 3-7]. 
Interestingly, senescent cells have also been observed in 
certain aged or damaged tissues and there is growing 
evidence that senescence checkpoints can affect the 
regenerative reserve of tissues and organismal aging [8-
11]. However, senescence may also have positive 
effects on organ maintenance by limiting pathological 
responses to acute forms of injury such as fibrotic 
scarring in response to chemical induced liver injury 
[12]. 
 
Over the past years it was also shown that senescent 



















































ing a myriad of cytokines and growth factors. 
Interestingly, this “senescence associated secretory 
phenotype (SASP)” seems to be a double edged sword 
regarding tumor initiation and maintenance:  
 
i)  On the one hand, it has been shown that the 
SASP can have pro-tumorigenic effects. In an 
experimental system it was shown that senescent 
mesenchymal cells can enhance the tumorigenicity of 
surrounding breast cancer cells [13].  
ii)  Similarly, it is possible that the SASP enhances 
selection of transformed cell clones in aged organ 
systems. It has been shown that loss of proliferative 
competition of non-transformed cells can accelerate 
leukemogenesis [14]. It remains to be seen whether 
aberrant secretion of cytokines and growth factors by 
the SASP can accelerated this process in aged and 
chronically damage organ systems.  
iii)    In contrast to its pro-tumorigenic aspect, the 
SASP could also have anti-tumor effects.  A recent study 
showed that in a mosaic liver cancer mouse model the 
activation of p53 induced senescence, an upregulation of 
inflammatory cytokines, and activation of innate immune 
responses leading to tumour cell clearance [15].  
iv)  In further support that the SASP could have 
anti-tumor activities, a series of recent papers showed 
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cell cycle arrest via an autoregulatory feedback loop [16, 
17] or induces apoptosis of tumor cells [18]. 
 
In addition to its effects on tumorigenesis, the SASP 
could also influence tissue aging. Studies on aging 

















































rimental evidence for an in vivo activation of the SASP 
in response to telomere dysfunction [19]. Interestingly, 
this  in vivo SASP provoked alterations in stem cell 
differentiation (skewing of hematopoiesis towards 
reduction in lymphopoiesis and enhancement of 
















































In  contrast  senescence  of  non‐transformed  cells  in  aging  organs  may  lead  to  loss  of  proliferative
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and carcinogenesis, it appears to be of utmost 
importance to decipher regulatory pathways controlling 
the SASP. In a current publication, Bhaumik et al. have 
identified 2 microRNAs (miR-146a/b) that negatively 
regulate the secretion of IL-6 and IL-8 – two of the 
SASP [20].  The authors show that these microRNAs 
are up-regulated at late stages of senescence, many days 
after a permanent cell cycle arrest has been established. 
Interestingly, the inhibitory miRs are most strongly up-
regulated in senescence of cell lines that show a strong 
SASP but not in cell lines characterized by a weak 
SASP. The authors propose a new concept indicating 
that miRs 146a and b function in a negative feedback 
loop preventing an over-activation of the SASP in 
senescent cells. The authors present some initial data 
suggesting that activation of this negative feedback loop 
involves IL-1 receptor, IRAK-1, and NFκB signalling 
leading to an up-regulation of miRs-146a and b. A 
direct proof that this proposed feedback loop suppresses 
over-activation of the SASP remains to be demonstrated 
in future studies. The authors show that blockage of IL-
1-receptor signalling prevents both the up-regulation of 
miRs-146a and b as well as Il-6 secretion. To confirm 
their new concept, it would be important to show that a 
selective blockage of miRs-146a and b results in over-
activation of the SASP.   
  
The work by Bhaumik et al. places mir-146a/b as 
central players to control IL-6 and IL-8 expression 
within the SASP. MicroRNAs are emerging therapeutic 
targets because their expression levels can be effectively 
modulated via the use of antagomirs [see for example 
21]. Also, for increasing microRNA expression, 
microRNAs can be delivered into cells in vivo [see for 
example 22]. Therefore, it will be interesting to 
functionally test the impact of mir-146 inhibition on 
tumorigenesis and aging in relevant mouse models. 
Such studies will be of particular interest, as recent 
work showed that IL-6 secretion by senescent cells is 
relevant for initiating and maintaining the senescene 
response via an autocrine loop [17]. A reduction of 
miR-146 could increase IL-6 levels in senescent cells, 
which should stabilize the senescence program and 
reduce the risk of malignant transformation. 
Furthermore, it can be speculated that reduction of mir-
146 a/b will increase NfκB activation via IRAK1. As 
NfκB is modulating the expression of various 
inflammation associated genes, this may also lead to 
increased clearance of senescent tumor cells by the 
innate immune system. However, it should be 
mentioned that Il-6 secreted by senescent cells can also 
act as a mitogen for surrounding cells, thus potentially 
increasing the risk of malignant transformation [13, 17]. 
Besides its function in SASP modulation, miR-146 was 
also reported to target the mRNAs of the BRCA1 and 
BRCA2 tumor suppressors. In a recent study a G to C 
polymorphism in miR-146, which leads to an increased 
processing and release of the mature microRNA, can 
predict an early onset of breast cancer [23].  
 
Taken together, the study of Bhaumik et al. opens an 
interesting new research area dealing with the gene 
regulatory mechanisms that control activation of the 
SASP. Given the diverse roles of the SASP in 
modulating tumor progression, immune surveillance of 
damaged cells, and the stabilization of the senescence 
arrest itself, it will be of great interest to analyse the 
influence of SASP regulatory pathways during aging 
and cancer.  
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